GT
ALLO icon

Glenmede Trust’s Allogene Therapeutics ALLO Stock Holding History

Glenmede Trust’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.5K Buy
+18,980
New +$41.7K ﹤0.01% 1445
2020
Q4 		– Sell
-150
Closed -$5K – 1232
2020
Q3 		$5K Hold
150
– – ﹤0.01% 2078
2020
Q2 		$6K Hold
150
– – ﹤0.01% 2012
2020
Q1 		$3K Hold
150
– – ﹤0.01% 2768
2019
Q4 		$3K Buy
+150
New +$4.13K ﹤0.01% 2768

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Glenmede Trust's ALLO Position: Q2 2026 in Review

Glenmede Trust opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 18,980 shares worth $39.5K. The stake represents ﹤0.01% of the portfolio and ranks #1445 among its holdings. This is a return to the name: Glenmede Trust previously reported a position in ALLO as recently as Q3 2020.

Glenmede Trust first reported a position in ALLO in Q4 2019 and has held it in 5 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Glenmede Trust held 18,980 shares of Allogene Therapeutics worth $39.5K as of Q2 2026.
  • Allogene Therapeutics was a new Glenmede Trust position in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #1445 holding.
  • Glenmede Trust first reported a position in Allogene Therapeutics in Q4 2019 and has held it in 5 quarters since.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.